The Federal Trade Commission asked a federal judge to hold “pharma bro” Martin Shkreli in contempt for failing to provide the agency with information needed to determine whether he is violating an order that permanently banned him from working in the pharmaceutical industry.
In a motion filed federal court in New York, the FTC and seven state regulators argued that Shkreli has failed to comply with their requests to provide documents and sit for an interview as part of their investigation into whether he violated the ban by forming and operating his new company, which is called Druglike Inc.
According to its website, the company claims it can use a software platform for “democratizing the access, costs and rewards of early-stage drug discovery.” In a press release issued last July, Druglike maintained it is a “blockchain/Web3 software company and not a pharmaceutical company. Druglike is not engaged in pharmaceutical research or drug development.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
